Truist Financial Raises Integer (NYSE:ITGR) Price Target to $150.00

Integer (NYSE:ITGR) had its price objective increased by Truist Financial from $145.00 to $150.00 in a research note published on Monday, Benzinga reports. Truist Financial currently has a buy rating on the medical equipment provider’s stock.

Other equities analysts have also recently issued research reports about the company. Oppenheimer assumed coverage on Integer in a report on Tuesday, July 16th. They set an “outperform” rating and a $135.00 target price for the company. Benchmark restated a “buy” rating and issued a $130.00 price objective on shares of Integer in a report on Wednesday, October 2nd. Bank of America raised their price objective on Integer from $135.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Finally, Citigroup raised their price objective on Integer from $124.00 to $130.00 and gave the company a “neutral” rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $138.71.

Integer Price Performance

ITGR stock opened at $131.06 on Monday. The stock has a 50-day moving average price of $126.20 and a two-hundred day moving average price of $120.41. The stock has a market cap of $4.39 billion, a PE ratio of 45.35, a price-to-earnings-growth ratio of 1.86 and a beta of 1.08. The company has a current ratio of 3.29, a quick ratio of 1.96 and a debt-to-equity ratio of 0.73. Integer has a 1 year low of $69.40 and a 1 year high of $133.53.

Integer (NYSE:ITGR) last released its earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.06. The firm had revenue of $436.20 million during the quarter, compared to analysts’ expectations of $437.00 million. Integer had a return on equity of 11.48% and a net margin of 6.31%. The company’s revenue was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.14 EPS. Equities analysts forecast that Integer will post 5.3 EPS for the current fiscal year.

Insider Activity at Integer

In related news, Director Jean M. Hobby sold 11,960 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $119.66, for a total value of $1,431,133.60. Following the completion of the sale, the director now directly owns 2,280 shares in the company, valued at approximately $272,824.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Integer

Several hedge funds have recently bought and sold shares of ITGR. Quadrature Capital Ltd acquired a new stake in Integer during the fourth quarter worth approximately $378,000. HighPoint Advisor Group LLC acquired a new stake in Integer during the fourth quarter worth approximately $221,000. Canandaigua National Bank & Trust Co. acquired a new stake in Integer during the first quarter worth approximately $233,000. Congress Asset Management Co. MA lifted its position in Integer by 7.5% during the first quarter. Congress Asset Management Co. MA now owns 453,260 shares of the medical equipment provider’s stock worth $52,886,000 after acquiring an additional 31,736 shares during the last quarter. Finally, Guidance Capital Inc. acquired a new stake in Integer during the first quarter worth approximately $500,000. 99.29% of the stock is currently owned by institutional investors and hedge funds.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.